FANTA SUWANEH: Open Payments
NPI 1497340228 · GRAPEVINE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,303 in 86 payments from 15 companies in 2025. Trend: 2023 $985 · 2024 $1,300 · 2025 $2,303
Food & beverage: $2,106Education: $196
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 13 | $416 |
| AstraZeneca Pharmaceuticals LP | 18 | $409 |
| CSL Behring | 8 | $311 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $224 |
| GlaxoSmithKline, LLC. | 7 | $221 |
| Novartis Pharmaceuticals Corporation | 6 | $129 |
| SANOFI-AVENTIS U.S. LLC | 1 | $98 |
| Galderma Laboratories, L.P. | 4 | $82 |
| Arcutis Biotherapeutics, Inc. | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
Products named: DUPIXENT, Andembry, FASENRA, NEFFY, NUCALA, NEMLUVIO, TRELEGY ELLIPTA, Zoryve.
Industry payments across TX — which companies pay providers there.
